Because Expertise Matters
Join Cyberounds®, an online education community for health professionals Sign Up

Log In

Category

Hematology Oncology

The Hematology/Oncology Conference is moderated by Robert G. Lerner, M.D., Professor of Medicine at New York Medical College.

This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

Emerging Treatments In Acute Myeloid Leukemia (AML)

Several investigational agents offer hope to patients with AML.
Authors: Mary-Elizabeth M. Percival, M.D., M.S. and Roland B. Walter, M.D., Ph.D., M.S.
Estimated Time: 1 Hour
More

More More

Robert G. Lerner, M.D.

Hematology Oncology

Dr. Robert G. Lerner, Cyberounds® Hematology/Oncology moderator, is Professor and Vice Chairman, Department of Medicine and Professor of Pathology at New York Medical College and is board certified in both hematology and medical oncology. A Phi Beta Kappa graduate of NYU and its medical school, Bob did his postgraduate training at Bellevue, Montefiore Hospital and USC. He is a recipient of an NIH Research Career Development Award and is Chief, Hematology, Westchester County Medical Center. Thromboembolic disease and the control of coagulation are Dr. Lerner's major areas of research interest.

Within the past 12 months, Dr. Lerner has received research/grant support from Sanofi-Aventis and Boehringer Ingelheim, and been on the Speakers Bureau for Eisai, GlaxoSmithKline and Sanofi-Aventis.

Last Update: 2/21/2021

More More

More Hematology/Oncology Courses

Alcohol Abuse and Cancer

Authors: By Danilo De Gregorio, Ph.D.
Estimated Time: 0 Hours
More

AML2

Estimated Time: 6 Hours
More

Unexplained Bleeding in Hospitalized Patients

While some disorders are more readily apparent than others, not all bleeding is straightforward or has a readily identifiable cause.
Authors: Meera B. Chitlur, M.D.
Estimated Time: 1 Hour
More

Lung Cancer Chemoprevention

Despite advances in lung cancer chemotherapy, there is a pressing need for effective lung cancer chemoprevention beyond smoking cessation.
Authors: Robert L. Keith, M.D.
Estimated Time: 1 Hour
More

Molecularly Targeted Therapy for Malignant Brain Tumors

Neuro−oncology is focusing on the uses of molecularly targeted agents in the adjuvant setting.
Authors: Nicole A. Shonka, M.D., and Mark R. Gilbert, M.D.
Estimated Time: 1 Hour
More